John Freiberg, MD
Neurology · Merrero, LANPI 1609812791
Payments from drug & device makers
Across 68 payments — averaging $20.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- UCB, Inc.$276
- Supernus Pharmaceuticals, Inc.$170
- AbbVie$162
- AstraZeneca$152
- Silk Road Medical, Inc.$92
- Amgen$74
- plus $455 from 12 others
What the payments were for
- Food & beverage$1,380100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| UCB, Inc. | 14 | $276 |
| Supernus Pharmaceuticals, Inc. | 6 | $170 |
| AbbVie(2 entities) | 9 | $162 |
| AstraZeneca(2 entities) | 10 | $152 |
| Silk Road Medical, Inc. | 1 | $92 |
| Amgen(2 entities) | 4 | $74 |
| Eisai Inc. | 3 | $58 |
| Sanofi | 3 | $57 |
| Neurelis, Inc. | 3 | $56 |
| Argenx US, Inc. | 2 | $43 |
| Teva Pharmaceuticals USA, Inc. | 2 | $40 |
| Adamas Pharmaceuticals, Inc. | 2 | $40 |
| Biohaven Pharmaceuticals, Inc. | 2 | $38 |
| SK Life Science, Inc. | 2 | $37 |
| Grifols USA, LLC | 2 | $34 |
| Johnson & Johnson | 1 | $23 |
| Pfizer | 1 | $16 |
| Boston Scientific | 1 | $13 |
How this compares
$1,380 in reported general payments places this provider in the 40th percentile of 225 neurology providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Lacosamide | 52 | $5,866 |
| Morphine Sulfate ErMorphine Sulfate | 36 | $1,421 |
| Carbamazepine ErCarbamazepine | 15 | $1,174 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 36 | $1,168 |
| Carbamazepine | 20 | $996 |
| Levetiracetam | 37 | $983 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 14 | $556 |
| Gabapentin | 19 | $531 |
| Phenobarbital | 20 | $529 |
| Divalproex Sodium | 13 | $450 |
| Divalproex Sodium ErDivalproex Sodium | 11 | $433 |
| Mirtazapine | 33 | $413 |
| Prochlorperazine Maleate | 13 | $303 |
| Baclofen | 27 | $292 |
| Ketorolac Tromethamine | 14 | $270 |
Paid to pharmacies, not to this prescriber.
Other neurology in Merrero
- Ariel Antezana AntezanaAlexandria$2.5M
- Jon OlsonBaton Rouge$1.7M
- Bridget BagertNew Orleans$1.4M
- Carol RedillasChalmette$1.3M
- Joseph TarsiaNew Orleans$1.2M
- Angela TraylorNew Orleans$941K
- Meghan HarrisShreveport$698K
- Maria Carmen WilsonCovington$681K
- Kevin CallerameBaton Rouge$420K
- Gerald CaleganBaton Rouge$400K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.